Company Description
Genentech Inc. The Group's principal activities are to discover, develop, manufacture and commercialize biotherapeutics for unmet medical needs. The Group manufactures and markets biotechnology products and licenses several additional products to ...
More
Related Business Topics
Breaking News
Reuters - 32 minutes ago
SOUTH SAN FRANCISCO, Calif.--(Business Wire)-- Exelixis, Inc. (NASDAQ:EXEL) announced today that Charles Butler, the company's vice president, investor relations and corporate communications, will present at Piper Jaffray's 21st Annual Healthcare ...
Forbes.com - 45 minutes ago
BusinessWire - Exelixis, Inc. (NASDAQ:EXEL) announced today that Charles Butler, the company's vice president, investor relations and corporate communications, will present at Piper Jaffray's 21st Annual Healthcare Conference at 1:30 p.m. EST / 10:30 ...
Reuters - 8 hours ago
* Roche CEO confident will meet new drugs sales goal * Sees pharma unit gaining market share ZURICH, Nov 25 (Reuters) - Swiss drugmaker Roche's (ROG.VX) pharma and diagnostics units will significantly outpace the market this year, the group's head was ...
Forbes.com - November 24, 2009 6:54 AM
BusinessWire - Exelixis, Inc. (NASDAQ:EXEL) announced today that it will hold its Fifth Annual R&D Day on Wednesday, December 2, 2009 from 10:00 a.m. EST / 7:00 a.m. PST to 2:00 p.m. EST / 11:00 a.m. PST in New York. Exelixis management will discuss the ...
Forbes.com - November 23, 2009 4:17 AM
SOUTH SAN FRANCISCO, Calif. 'We are very pleased to be able to recruit directors of this caliber. Their talents will be important as we make plans to move our new company forward after the merger,' said Michael Kranda, president and chief executive ...
